Everyday Alpha

Everyday Alpha

A no-fluff daily newsletter with one high-conviction stock pick delivered straight to your inbox, every market day.

Archive

EA NewsletterEA Newsletter
The Beaten-Down Healthcare Name Setting Up a Breakout

The Beaten-Down Healthcare Name Setting Up a Breakout

The setup nobody's talking about while the crowd chases oil and chips

EA NewsletterEA Newsletter
A Beaten-Down Biotech Is Setting Up for a Rerating Before Its Big Data Week

A Beaten-Down Biotech Is Setting Up for a Rerating Before Its Big Data Week

A quiet upgrade just cracked open a $45 leap in expectations. Guess who?

EA NewsletterEA Newsletter
Is Wall Street Finally Catching Up to the Agentic Commerce Story?

Is Wall Street Finally Catching Up to the Agentic Commerce Story?

Two analysts pulled the trigger on the same name within 24 hours—coincidence?

EA NewsletterEA Newsletter
The Cloud Security IPO Where a $7 Million Insider Bet Just Landed

The Cloud Security IPO Where a $7 Million Insider Bet Just Landed

A $7.2M insider buy just landed on a beaten-down cloud security IPO. The Street's still calling it expensive.

EA NewsletterEA Newsletter
The Restaurant Tech Reset Goldman Just Called a Buy

The Restaurant Tech Reset Goldman Just Called a Buy

A $17B restaurant tech name just caught a Goldman Buy upgrade. The setup is tight.

EA NewsletterEA Newsletter
The Marine Freight Play With a Fresh $182 Target and a Lot of Room to Run

The Marine Freight Play With a Fresh $182 Target and a Lot of Room to Run

Wall Street's favorite hidden mover just got upgraded—and barely anyone's watching yet.

EA NewsletterEA Newsletter
When an Insider Acquisition Signals Confidence in the Turnaround

When an Insider Acquisition Signals Confidence in the Turnaround

Someone at the top just bought the dip before Main Street noticedA key executive just received a significant stock award in her own company.

EA NewsletterEA Newsletter
The Blood Test That Just Got a 40% Price Target Bump

The Blood Test That Just Got a 40% Price Target Bump

An FDA-cleared blood test just triggered a 40% price target hike. And the biggest catalyst hasn't hit yet

EA NewsletterEA Newsletter
The Fintech Adding 800,000 New Clients With a $50M Buyback Running in the Background

The Fintech Adding 800,000 New Clients With a $50M Buyback Running in the Background

A $50M buyback just kicked off at a fintech Goldman calls its top pick. And the client growth math is wild.

EA NewsletterEA Newsletter
The Biotech Sitting on a Fresh Launch and a Proven Pipeline Asset

The Biotech Sitting on a Fresh Launch and a Proven Pipeline Asset

A $17B specialty biotech just launched a brand-new drug in an underserved endocrine market, and early scripts are already tracking ahead of internal forecasts. On top of that, Phase 2 data for a first-in-class schizophrenia candidate already came back positive. The setup here is asymmetric.

EA NewsletterEA Newsletter
The Small-Cap Biotech Setting Up for a Second Act

The Small-Cap Biotech Setting Up for a Second Act

The market caught the rare-disease approval this spring. What it hasn't priced in is the second, third, and fourth act still building in the same pipeline. That's where the asymmetric setup lives.

EA NewsletterEA Newsletter
The $11 Billion Eye in the Sky That Every Government Wants a Piece Of

The $11 Billion Eye in the Sky That Every Government Wants a Piece Of

The geopolitical map is on fire, and one $11B name owns the map itself.

FirstBack
12345678
Next Last